The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...
Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...
Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...
Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company's potential treatment for a rare disease. The FDA's Decision on BHVN's Drug Candidate The FDA agreed to review BHVN's ...
Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...
Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results